Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology posts investor presentation and summary on its website

Neutral Impact 1 of 5 other Written later

MAIA Biotechnology filed a Form 8-K furnishing a company presentation (Exhibit 99.1) and a summary (Exhibit 99.2) that management may use in investor presentations on or after October 6, 2026. The filing contains no financial results, guidance, or new transaction terms, and the company states the materials are summary information to be read alongside its other SEC filings.

Key points

  • Presentation and summary were both posted to the company website on October 6, 2026.
  • Filing covers Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits 99.1, 99.2 and 104).
  • Materials contain forward-looking statements tied to preclinical and clinical studies, regulatory approvals and market acceptance.

The filing

CompanyMAIA Biotechnology, Inc. (MAIA)
Form8-K, current report
Filed with the SECOct 6, 2026, 8:15 AM ET
Accession number0001493152-26-045865

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.